But that's old news. ImmunoGen announced its second-quarter results after the market opened on Friday. It was a much different story this time around. Here are the highlights from the company's Q2 update.
By the numbers
ImmunoGen announced that its revenue jumped nearly 67% to $15.5 million from the prior-year period total of $9.3 million. Analysts estimated that the company's revenue for the second quarter would come in at $9.48 million.
The biotech reported a net loss of $43.4 million, or $0.29 per share, under generally accepted accounting principles (GAAP), compared to $41.6 million, or $0.31 per share, in the same period in 2018. Wall Street was expecting a Q2 adjusted net loss of $0.33 per share.
ImmunoGen's cash and cash equivalents as of June 30, totaled $239.8 million. The company's cash position decreased from $262.3 million on hand at the end of 2018.
Behind the numbers
That big revenue jump stemmed in part from higher noncash royalty revenue of $10.2 million in Q2 versus $7.2 million in the prior-year period. ImmunoGen also benefited from higher license and milestone fees, including a $5 million milestone payment from its license agreement with Roche.
But ImmunoGen's bottom line deteriorated again despite the increase in revenue. The culprit was increased operating expenses. While the company's research and development costs declined significantly from the prior-year period, ImmunoGen recorded a large restructuring charge in Q2 that caused its net loss to worsen.
Since ImmunoGen doesn't have an approved product on the market yet, its pipeline development is in many ways more important than its financial results. The company made progress with its pipeline in the second quarter, including:
- Presenting mature data for mirvetuximab in combination with bevacizumab from the Forward II expansion cohort at the American Society of Clinical Oncology (ASCO) Annual Meeting in June.
- Accelerating patient enrollment in the Forward II study.
- Filing to begin clinical studies evaluating a combination of IMGN632, Vidaza, and Venclexta in relapsed/refractory acute myeloid leukemia (AML).
ImmunoGen anticipates revenue for the full year to come in between $40 million and $45 million. The company also expects operating expenses to be between $175 million and $180 million. Perhaps the most important financial metric is that ImmunoGen looks for its cash position to be between $165 million and $170 million at the end of the year.
The biotech hopes to extend its cash runway through the readout of the pivotal study of mirvetuximab in treating platinum-resistant ovarian cancer. This study should begin by the end of the year after ImmunoGen meets with regulators in the U.S. and Europe.